GT Biopharma Provides Enrollment Update On GTB-3650 Phase 1 Trial In Patients With Relapsed Or Refractory (R/R)CD33 Expressing Hematologic Malignancies
ReutersOct 8, 2025 1:18 PM
Oct 8 (Reuters) - GT Biopharma Inc GTBP.O:
GT BIOPHARMA PROVIDES ENROLLMENT UPDATE ON GTB-3650 PHASE 1 TRIAL IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) CD33 EXPRESSING HEMATOLOGIC MALIGNANCIES
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
OpenAI's Dev Day 2025: How ChatGPT's App Ecosystem Is Redefining the Internet
Two years ago, OpenAI's first Dev Day felt like a startup showing off its breakthrough product. ChatGPT had 100 million weekly users and processed 300 million API tokens per minute—numbers that made headlines and seemed impossibly large. Fast-forward to today, and those figures look almost modest. CTradingKey
3 hours ago
Synopsys (SNPS): Strategic Opportunities and Risks Amid 40% Drawdown
Chip giant Synopsys teetering on the edge? The ultimate "pick-and-shovel" supplier in the AI frenzy, but hammered by China's sudden market freeze and export clamps, sending shares crashing 40%! Is that $35 billion Ansys mega-deal a rescue rope or a bigger sinkhole? Dive into the EDA powerhouse's naiTradingKey
5 hours ago
-8a7a081ca049441dae56d6b7cc6440c4.jpg)
FOMC October Meeting Minutes: How Should Investors Respond?
In the context of the U.S. government shutdown and a period of limited economic data, the Federal Reserve’s release of its latest monetary policy meeting minutes and officials’ statements on 8 October will be particularly significant.TradingKey
Tue, Oct 7
U.S. Government Shutdown Commentary: Is a Stock Market Crash Imminent? Will Gold Prices Continue to Surge?
TradingKey - On 1 October 2025, the U.S. federal government officially entered a shutdown, impacting various asset classes. This article analyses two key markets most affected—U.S. equities and gold—to help investors identify potential opportunities.TradingKey
Wed, Oct 1
ASML Q2 FY2025 Earnings Review: Strong Growth and High-NA EUV Breakthrough Shadowed by 2026 Uncertainty
ASML Holding N.V. (NASDAQ: ASML) released its Q2 FY2025 earnings on July 16, 2025, exceeding market expectations with robust net sales and net bookings, though the stock fell around 10% due to cautious guidance for 2026 amid geopolitical uncertainties.TradingKey
Mon, Jul 14
